Alterity Therapeutics Ltd ShareCafe Small Cap “Hidden Gems” Webinar Transcript
Thank you to the audience and very happy that you've joined me today and taking time out of your day. So, you can hear about the excellent progress that we've been making in the recent past as we we've been developing novel treatments for neurodegenerative disorders.
Next slide. These are forward-looking statements. Next slide.
At Alterity, we are developing disease-modifying therapies that really address the underlying pathology and the aim is to try and slow the disease progression. Our novel drug candidate, which we refer to as ATH434 targets proteins that are implicated in the neurodegenerative process, and this includes diseases such as Parkinson's and MSA.
Our first indication, multiple system atrophy or MSA has a devastating degenerative condition with no approved treatments and it has achieved orphan drug designation in the United States as well as in the European Union. I'll be telling you in a moment about an ongoing Phase 2 clinical trial to demonstrate target engagement and efficacy of this drug in the target population.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
